BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company), reports that the U.S. FDA has approved the second drug provided in the newly launched BD Simplist line of ready-to-administer prefilled generic injectables. The second BD Simplist product to launch is Metoclopramide Injection, USP, an injectable antiemetic, BD Rx reported in a press release. The first drug, BD Simplist Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine, was launched on March 27, 2013.
BD Simplist prefilled injectables are designed to decrease the number of steps in the traditional vial and syringe injection sequence, aiming to reduce the potential risk of medication errors. Clinicians reportedly perform up to 20 steps when using a traditional vial and syringe for injection. But with BD Simplist prefilled injectables, the injection sequence is reduced to approximately 12 steps, BD Rx reports.
"After a successful launch of BD Simplist prefilled injectables, we're excited to be coming out with a second drug that is commonly used by clinicians. This is just the beginning of our new line of prefilled injectable products," said Mark Sebree, President, BD Rx, in the press release. "BD has a long-standing reputation for delivering high-quality, high-volume products. Our work at BD Rx is no different, as we bring that same commitment to quality and patient safety to our new work in generic drug manufacturing."
BD Rx intends to launch 20 to 30 drugs in its BD Simplist line, targeting generic injectables in doses most commonly relied on by clinicians in both the hospital and surgical center settings, the company reports.
For more information, please visit www.bd.com .
Source: BD via PRNewswire